News & Updates

Skin sensitization and dermatitis appear to be common among workers exposed to high concentrations of epoxy, despite comprehensive skin protection, according to a study.

New drug applications approved by US FDA as of 16-30 Sep 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H₁-antihistamine (H₁-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.

Depending on the model being used, recalibration of risk scores using contemporary population-level data may improve risk stratification for statin therapy, suggests a study.

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.

Use of aspirin offers health benefits to older individuals with elevated lipoprotein(a) genotypes by preventing cardiovascular events, suggests a study.